Cargando…

Treatment beyond progression and locoregional approaches in selected patients with BRAF-mutated metastatic melanoma

The clinical management of BRAF-mutated metastatic melanoma had an important turning point after the introduction of the targeted therapy. Despite the efficacy and good tolerability of this treatment, the development of resistance mechanisms causes disease progression. The aim of this review is to i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Serra, Francesco, Faverio, Carlotta, Lasagna, Angioletta, Barruscotti, Stefania, Dominioni, Tommaso, Benazzo, Marco, Pedrazzoli, Paolo, Chiellino, Silvia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioExcel Publishing Ltd 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366503/ https://www.ncbi.nlm.nih.gov/pubmed/34457014 http://dx.doi.org/10.7573/dic.2021-3-1

Ejemplares similares

Lights and shadows on the role of rhG-CSF in cancer patients during the COVID-19 pandemic and future perspectives of research
por: Lasagna, Angioletta, et al.
Publicado: (2021)

The Role of Pre-treatment Inflammatory Biomarkers in the Prediction of an Early Response to Panitumumab in Metastatic Colorectal Cancer
por: Lasagna, Angioletta, et al.
Publicado: (2022)

COVID-19 and breast cancer: may the microbiome be the issue?
por: Lasagna, Angioletta, et al.
Publicado: (2020)

Case report: Successful outcome of COVID-19 in the context of autologous hematopoietic stem cell transplantation: The impact of the anti-SARS-CoV-2 vaccine and early remdesivir
por: Lasagna, Angioletta, et al.
Publicado: (2022)

Long-COVID in Patients with Cancer Previously Treated with Early Anti-SARS-CoV-2 Therapies in an Out-of-Hospital Setting: A Single-Center Experience
por: Lasagna, Angioletta, et al.
Publicado: (2023)

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
por: Spagnolo, Francesco, et al.
Publicado: (2014)

Clinical significance of BRAF mutations in metastatic melanoma
por: Chang, David Z, et al.
Publicado: (2004)

Targeting the Cellular Signaling: BRAF Inhibition and Beyond for the Treatment of Metastatic Malignant Melanoma
por: Ades, Felipe, et al.
Publicado: (2012)

Effectiveness of the available early therapies in reducing severe COVID-19 in non-hospitalized patients with solid tumors on active treatment
por: Lasagna, Angioletta, et al.
Publicado: (2022)

Occult hepatitis B in patients with cancer during immunotherapy with or without chemotherapy: A real-life retrospective single-center cohort study
por: Lasagna, Angioletta, et al.
Publicado: (2023)

Proteomic Profile and In Silico Analysis in Metastatic Melanoma with and without BRAF Mutation
por: Garrisi, Vito Michele, et al.
Publicado: (2014)

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019)

Efficacy of BRAF Inhibitors in Asian Metastatic Melanoma Patients: Potential Implications of Genomic Sequencing in BRAF-Mutated Melanoma()()
por: Kim, Hee Kyung, et al.
Publicado: (2016)

Beyond BRAF: where next for melanoma therapy?
por: Fedorenko, I V, et al.
Publicado: (2015)

Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a novel marker for patients with BRAF-mutated metastatic melanoma
por: Audrito, Valentina, et al.
Publicado: (2018)

Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma
por: Hassel, Jessica C., et al.
Publicado: (2017)

Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma
por: Curl, Patti, et al.
Publicado: (2014)

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015)

The relevance of BRAF G469A mutation in determining the response to therapy in metastatic melanoma
por: Porcelli, Letizia, et al.
Publicado: (2015)

The Impact of Drug–Drug Interactions on the Toxicity Profile of Combined Treatment with BRAF and MEK Inhibitors in Patients with BRAF-Mutated Metastatic Melanoma
por: Mezi, Silvia, et al.
Publicado: (2023)

In reply to: “A COVID-19 screening tool for oncology telephone triage”
por: Lasagna, Angioletta, et al.
Publicado: (2020)

Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations
por: Giunta, Emilio Francesco, et al.
Publicado: (2020)

BRAF and beyond: Tailoring strategies for the individual melanoma patient
por: Jarkowski, Anthony, et al.
Publicado: (2014)

Development of hepatitis triggered by SARS-CoV-2 vaccination in patient with cancer during immunotherapy: a case report
por: Lasagna, Angioletta, et al.
Publicado: (2022)

Lingual metastasis from renal cell carcinoma: a case report and literature review
por: Ganini, Carlo, et al.
Publicado: (2012)

Dabrafenib: A New Therapy for Use in BRAF-Mutated Metastatic Melanoma
por: McGettigan, Suzanne
Publicado: (2014)

T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients
por: Borch, Troels Holz, et al.
Publicado: (2014)

Correction: Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma
por: Curl, Patti, et al.
Publicado: (2015)

Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma
por: Ryu, Sunhyo, et al.
Publicado: (2017)

Advances in Intralesional Therapy for Locoregionally Advanced and Metastatic Melanoma: Five Years of Progress
por: DePalo, Danielle K., et al.
Publicado: (2023)

Melanoma Targeted Therapies beyond BRAF-Mutant Melanoma: Potential Druggable Mutations and Novel Treatment Approaches
por: Khaddour, Karam, et al.
Publicado: (2021)

Correction: Proteomic Profile and In Silico Analysis in Metastatic Melanoma with and without BRAF Mutation
Publicado: (2015)

Vemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic Melanoma
por: Shelledy, Lindsay, et al.
Publicado: (2015)

Uncommon BRAF Mutations Associated with Durable Response to Immunotherapy in Patients with Metastatic Melanoma
por: Swofford, Brenen P., et al.
Publicado: (2017)

Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma
por: Gouda, M.A., et al.
Publicado: (2021)

The Prognostic Value of Locoregional Interventions for BRAF V600E Metastatic Colorectal Cancer: A Retrospective Cohort Analysis
por: Ye, Liu-Fang, et al.
Publicado: (2021)

How we treat locoregional melanoma
por: Troiani, T., et al.
Publicado: (2021)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

The next generation of metastatic melanoma: uncovering the genetic variants for anti-BRAF therapy response
por: Pinto, Rosamaria, et al.
Publicado: (2016)

Hyperforin Enhances Heme Oxygenase-1 Expression Triggering Lipid Peroxidation in BRAF-Mutated Melanoma Cells and Hampers the Expression of Pro-Metastatic Markers
por: Cardile, Alessia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c7ptes59jr5ekk8eom6t1jvt4i